Loading
companiesCompany
Ascletis Pharma
Ascletis is a Hangzhou biotech listed in Hong Kong, first known for hepatitis C antivirals, which sponsors phase 3 cancer trials among its liver-disease and metabolic programmes.
Also called: Ascletis Pharmaceuticals Co., Ltd.Ascletis Pharma Inc.歌礼制药
Overview
Ascletis Pharma, headquartered in Hangzhou and listed in Hong Kong, began with direct-acting antivirals for hepatitis C in China and has since moved into liver disease, metabolic disease and oncology, including a PD-L1 antibody programme. ClinicalTrials.gov lists Ascletis as lead sponsor of a phase 3 cancer trial. Its phase 3 cancer trial tests the fatty acid synthase inhibitor ASC40 (denifanstat, TVB-2640) with bevacizumab in recurrent glioblastoma (NCT05118776), and it has a phase 1 trial of the oral PD-L1 inhibitor ASC61 in advanced solid tumours (NCT05287399).
Headquarters
Hangzhou, CN
Scorecard
All companies#390of 1244 companies, score 9
- phase 3 +3
- modalities +2
- registry trials +4
0 approved, 1 in phase 3, 0 earlier, 0 targets, 5 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 3small molecule
ASC40 is an experimental small-molecule drug from Ascletis Pharmaceuticals in phase 3 trials for glioma & glioblastoma, with its target not yet stated publicly.
Similar pages
- CompanyImmunitor
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma.
- CompanyDenovo Biopharma
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- CompanyGC Cell
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma.
- CompanyDiffusion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- CompanyPregLem
- CompanyMoleculin Biotech
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- CompanyAgennix